NervGen Pharma to Advance NVG-300 into Preclinical Proof-of-Concept Stage

New molecule demonstrates efficacy in a challenging SCI model Expanding pipeline into new indications of ischemic stroke and ALS   Vancouver, Canada June 25, 2024 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, today announced its plans for the […]

NervGen Pharma to Present at the 2nd Annual Spinal Cord Injury Investor Symposium

Vancouver, Canada, June 20, 2024 — NervGen Pharma Corp. (TSX-V: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced today that Mr. Mike Kelly, President & CEO, will be presenting a corporate update at the 2nd Annual Spinal Cord Injury Investor Symposium (“2nd SCIIS”), presented […]

NervGen Pharma Grants Stock Options

Vancouver, Canada. June 6, 2024 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced that the company has granted 950,000 incentive stock options to directors and consultants of the company exercisable at a price of $1.79 per share (the […]

NervGen Pharma Announces Results of Annual General Meeting of Shareholders

All resolutions submitted for approval were passed by shareholders Glenn Ives appointed as Chair of the Board John Ruffolo appointed as Chair of the Audit Committee   Vancouver, Canada, June 5, 2024 — NervGen Pharma Corp. (TSX-V: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, […]

NervGen Pharma to Present Two Posters at the American Spinal Injury Association 51st Annual Scientific Meeting

Vancouver, Canada, May 17, 2024 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF), a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced today that Daniel Mikol, MD, Ph.D., Chief Medical Officer, will be presenting two posters at the upcoming American Spinal Injury Association (ASIA) 51st  Annual Scientific […]

NervGen Pharma Reports Q1 2024 Financial Results and Operational Updates

Target for completing enrollment of the chronic cohort in the Phase 1b/2a clinical trial moved to Q3 2024 Subacute cohort protocol being amended to enhance feasibility and lessen burden on participants CA$23 million bought deal financing completed in March 2024 provides expected cash runway through Q3 2025   Vancouver, Canada, May 16, 2024 – NervGen […]

NervGen Files Management Information Circular and Announces Board of Directors Transition

Bill Radvak to transition to Board Advisor following decision to not stand for re-election to NervGen’s Board of Directors Annual General Meeting of Shareholders to be held on June 4, 2024   Vancouver, Canada, May 7, 2024 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a clinical-stage biotech company dedicated to […]

NervGen Engages Russo Partners LLC to Provide Public Relations Services

Vancouver, Canada, April 25, 2024 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced that it has engaged Russo Partners LLC (“Russo Partners”), a New York based full-service strategic communications firm to provide media […]

NervGen Pharma Reports 2023 Year-End Financial Results and Operational Updates

Anticipated completion of enrollment of the chronic cohort in the Phase 1b/2a clinical trial in Q2 2024 CA$23 million bought deal financing completed in March 2024 provides expected cash runway through Q3 2025 Fast Track designation granted by U.S. Food and Drug Administration (FDA) for NVG-291 in spinal cord injury   Vancouver, Canada April 17, […]

NervGen Completes $23 Million Bought Deal Financing

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES.   Vancouver, British Columbia March 28, 2024 – NervGen Pharma Corp. (“NervGen” or the “Company”) (TSXV: NGEN) is pleased to announce the closing of its previously announced public offering (the “Offering”) including the full exercise of the underwriters’ over-allotment […]